{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:15:23Z","timestamp":1793607323509,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study examines whether anterior mitral valve leaflet (AMVL) length is associated with response to mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Obstruction of the left-ventricular outflow tract (LVOT) in HCM has been associated with asymmetric septal hypertrophy and abnormalities of the mitral valve and sub-valvular apparatus. Mavacamten is a myosin-inhibitor shown to decrease LVOT gradient and improve functional status in patients with obstructive HCM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Measurements of cardiac structural elements were obtained from magnetic resonance imaging and echocardiography data among patients with obstructive HCM treated with mavacamten. Endpoints were effective mavacamten dose, defined as the dose required to achieve a Valsalva LVOT gradient &amp;lt;30\u2005mmHg, and rapid response to mavacamten therapy, defined as achieved Valsalva LVOT gradient &amp;lt;20\u2005mmHg within 8 weeks of initiation. Among 33 patients, patients with an effective dose of 5\u2005mg (n = 13) had a shorter AMVL length [20.00 (18.50, 20.80) mm] compared with patients with a dose of 10\u2005mg (n = 12) [23.30 (22.45, 26.10) mm] and 15\u2005mg (n = 8) [25.45 (24.20, 26.85) mm] (P &amp;lt; 0.001). After adjusting for age and sex, the 5\u2005mg dose was associated with a shorter AMVL length (P = 0.003). AMVL length was shorter in rapid responders [20.9 (19.9, 22.5) mm] compared with patients without a rapid response [24.9 (23.3, 26.5) mm] (P = 0.006).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Shorter AMVL length is associated with a lower effective dose and a rapid response to mavacamten. If confirmed in larger studies, AMVL length may inform optimal dosing of myosin inhibitors in obstructive HCM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjimp\/qyaf081","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:11:26Z","timestamp":1749712286000},"source":"Crossref","is-referenced-by-count":2,"title":["Anterior mitral valve leaflet length and response to mavacamten in obstructive hypertrophic cardiomyopathy"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-7539","authenticated-orcid":false,"given":"Danish","family":"Saleh","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis Y","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kifah","family":"Hussain","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinesh","family":"Appadurai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL 60611, USA"},{"name":"School of Medicine, The University of Queensland , Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Mueller","sequence":"additional","affiliation":[{"name":"The Hypertrophic Cardiomyopathy Program at the Bluhm Cardiovascular Institute , Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Garza","sequence":"additional","affiliation":[{"name":"The Hypertrophic Cardiomyopathy Program at the Bluhm Cardiovascular Institute , Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljash","family":"Cheema","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL 60611, USA"},{"name":"The Hypertrophic Cardiomyopathy Program at the Bluhm Cardiovascular Institute , Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-7119","authenticated-orcid":false,"given":"Dominic E","family":"Fullenkamp","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL 60611, USA"},{"name":"The Hypertrophic Cardiomyopathy Program at the Bluhm Cardiovascular Institute , Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera H","family":"Rigolin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL 60611, USA"},{"name":"The Hypertrophic Cardiomyopathy Program at the Bluhm Cardiovascular Institute , Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Narang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL 60611, USA"},{"name":"The Hypertrophic Cardiomyopathy Program at the Bluhm Cardiovascular Institute , Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C","family":"Cremer","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL 60611, USA"},{"name":"The Hypertrophic Cardiomyopathy Program at the Bluhm Cardiovascular Institute , Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL 60611, USA"},{"name":"The Hypertrophic Cardiomyopathy Program at the Bluhm Cardiovascular Institute , Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"2025070204072151200_qyaf081-B1","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"2025070204072151200_qyaf081-B2","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"83","author":"Writing Committee Members","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025070204072151200_qyaf081-B3","doi-asserted-by":"crossref","first-page":"e006657","DOI":"10.1161\/JAHA.117.006657","article-title":"Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy","volume":"7","author":"Lu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2025070204072151200_qyaf081-B4","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jacc.2016.01.071","article-title":"The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context","volume":"67","author":"Sherrid","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025070204072151200_qyaf081-B5","doi-asserted-by":"crossref","first-page":"e003132","DOI":"10.1161\/CIRCIMAGING.115.003132","article-title":"Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography","volume":"8","author":"Patel","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"2025070204072151200_qyaf081-B6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/hrt.2007.118018","article-title":"Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"94","author":"Kwon","year":"2008","journal-title":"Heart"},{"key":"2025070204072151200_qyaf081-B7","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1161\/01.CIR.85.5.1651","article-title":"Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy","volume":"85","author":"Klues","year":"1992","journal-title":"Circulation"},{"key":"2025070204072151200_qyaf081-B8","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.21037\/jtd-22-182","article-title":"Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review","volume":"14","author":"Guigui","year":"2022","journal-title":"J Thorac Dis"},{"key":"2025070204072151200_qyaf081-B9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"2025070204072151200_qyaf081-B10","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"key":"2025070204072151200_qyaf081-B11","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025070204072151200_qyaf081-B12","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2025070204072151200_qyaf081-B13","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025070204072151200_qyaf081-B14","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025070204072151200_qyaf081-B15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"2025070204072151200_qyaf081-B16","year":"2024"},{"key":"2025070204072151200_qyaf081-B17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2025070204072151200_qyaf081-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography","volume":"32","author":"Mitchell","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"2025070204072151200_qyaf081-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2025070204072151200_qyaf081-B20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.echo.2025.01.006","article-title":"Guidelines for the echocardiographic assessment of the right heart in adults and special considerations in pulmonary hypertension: recommendations from the American Society of Echocardiography","volume":"38","author":"Mukherjee","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"key":"2025070204072151200_qyaf081-B21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","article-title":"Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance","volume":"30","author":"Zoghbi","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"2025070204072151200_qyaf081-B22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jcmg.2024.02.014","article-title":"Mitral regurgitation in obstructive hypertrophic cardiomyopathy: insight from the VALOR-HCM study","volume":"17","author":"Cremer","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025070204072151200_qyaf081-B23","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal - Imaging Methods and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjimp\/advance-article-pdf\/doi\/10.1093\/ehjimp\/qyaf081\/63474208\/qyaf081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjimp\/article-pdf\/3\/2\/qyaf081\/63474208\/qyaf081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjimp\/article-pdf\/3\/2\/qyaf081\/63474208\/qyaf081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:07:34Z","timestamp":1751443654000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjimp\/article\/doi\/10.1093\/ehjimp\/qyaf081\/8160722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjimp\/qyaf081","relation":{},"ISSN":["2755-9637"],"issn-type":[{"value":"2755-9637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,12]]},"article-number":"qyaf081"}}